Cantor Fitzgerald Maintains Overweight on Rocket Pharmaceuticals, Raises Price Target to $10
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Cantor Fitzgerald analyst Josh Schimmer maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Overweight and raises the price target from $8 to $10.
Cantor Fitzgerald analyst Josh Schimmer maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Overweight and raises the price target from $8 to $10.